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over a 3-year time horizon, with a special focus on prophylaxis and treatment of 
invasive fungal infections (IFI). METHODS: This was a retrospective, single-center 
study on AML patients hospitalized for chemotherapy, neutropenia, and infections 
after myelosuppressive chemotherapy from January 2004 to December 2006. Data on 
occurrence of IFI, treatment patterns, and resource utilization were collected by chart 
review. Direct medical costs were calculated from hospital provider perspective. 
RESULTS: In total, 471 hospitalization episodes in 212 patients were eligible for 
analysis. Occurrence of IFI decreased from 5.9% in 2004 to 1.9% in 2006. Mean 
hospital stay decreased from 28.7 ± 17.9 days (2004) to 22.4 ± 11.8 days (2006) (P 
< 0.05). From 2004 to 2006, use of a single antifungal drug increased from 30.4% 
to 46.9% of episodes, whereas use of multiple antifungal drugs decreased from 24.4% 
to 13.1%. Single antifungal drug use was dominated by azoles and increased from 
23.7% (2004) to 43.4% of episodes (2006). Posaconzole monotherapy was applied 
in 26.7% of episodes. Use of liposomal amphotericin B declined from 21.4% to 3.8%, 
caspofungin from 19.3% to 8.1%, ﬂ uconazole from 25.2% to 11.9%, and voricon-
azole from 31.9% to 15.0%. Total costs per episode declined from c19,051 ± 19,024 
(2004) to c13,531 ± 9,260 (2006) (P < 0.05); main reduction was observed for anti-
mycotics, blood products, and hospital stay. CONCLUSIONS: These real-life data 
from a university hospital in Germany indicate that the antifungal management of 
AML patient hospitalized for chemotherapy, neutropenia, and infections after chemo-
therapy changed between 2004/5 and 2006. This change was accompanied by a 
decline in treatment costs. Results suggest that the introduction of posaconazole 
prophylaxis in 2006 has not only reduced the use of antifungal therapies but also the 
need for treatment with multiple antifungal drugs.
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Prostate cancer is the most common form of cancer in UK men and incidence is on 
the rise, primarily driven by increased screening. Low-risk prostate cancer has disease-
speciﬁ c survival consistently over 95%. Consequently, the UK has deemed radical 
treatments (RTs) comprising radical prostatectomy, radiotherapy, and brachytherapy 
as unnecessary for low-risk prostate cancer and recommends active surveillance (AS). 
AS does not address the disutility for patients living with cancer and in real-life over 
50% of patients proceed to RT. Alternative “focal therapies” for this patient popula-
tion are therefore generating interest. OBJECTIVES: Determine the cost-effectiveness 
of AS in the UK as practiced and contrast with focal therapy. METHODS: A Markov 
model was used to evaluate the cost-utility of treatments for low-risk prostate cancer. 
Input parameters for progression rates, efﬁ cacy, and side effects were derived from 
the literature. Biochemical and histological progression to RT plus patient choice were 
modeled. Hormonal treatment was included as salvage therapy. Age-related mortality 
rates were applied throughout the model. For focal therapy, all low-risk patients 
received treatment. Failure of treatment led to patients commencing AS, while bio-
chemical progression at any time led to RT. Costs were taken from the UK NHS 
perspective. RESULTS: Over 25 years, AS delivered 13.3 QALYs (3.5% discount rate 
applied). The QALY value was heavily weighted by the utility of 0.84 associated with 
AS. Focal therapy delivered improved QALYs (14.6) over the same period and could 
be delivered for cost parity with AS. Cost-effectiveness is discussed. CONCLUSIONS: 
UK guidelines recommend AS for low-risk prostate cancer but do not meet the needs 
of patients, evinced by low QoL and by many patients choosing RT. Hence, AS has 
“hidden costs” in the UK system and there is a place for alternative treatment 
approaches such as focal therapies.
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OBJECTIVES: To assess cancer-related costs and related predictors among elderly 
breast cancer patients in the United States. METHODS: A retrospective study was 
conducted in subjects aged ≥65 years and diagnosed with breast cancer between 
January 1, 2000 and December 31, 2005. Patients were identiﬁ ed from the SEER-
Medicare linked database that combines clinical information on cancer cases with 
longitudinal (1991–2006) Medicare claims. An index date was deﬁ ned as the date of 
the ﬁ rst observed breast cancer diagnosis. Costs (2009 US$) were aggregated from 
subjects’ index date until death, Medicare disenrollment, or database end (December 
31, 2006) and included breast cancer-related surgery, radiotherapy, chemotherapy, 
and other medical encounters carrying a breast cancer diagnosis. Generalized linear 
models with a log link function and gamma distribution were used to assess predictors 
of costs. Age, race, stage at diagnosis, hormone receptor status (ER/PR), nodal status, 
Charlson comorbidity score, and chemotherapy use were key explanatory variables. 
RESULTS: The majority of the 66,217 breast cancer subjects selected were aged 70 
to 79 years (47%), Caucasian (88%), and in localized stage (67%) at diagnosis. 
Median follow-up was 50 onths. Approximately 5% of cases were diagnosed in the 
metastatic stage with a median follow-up of 26 months. Approximately 73% of 
subjects with metastatic disease died during follow-up compared to 21% of localized 
cases. Cancer-related adjusted costs per patient were $55,120 (median $25,991) for 
all cases and $153,421, $82,789, and $38,099, for metastatic, regional, and local stage 
cases, respectively. Regional and metastatic stage at diagnosis, increased age, increased 
number of cancer-positive lymph nodes, negative estrogen/progesterone receptor 
status, and chemotherapy use were found to be signiﬁ cant (P < 0.001) predictors of 
higher costs. CONCLUSIONS: Clinical characteristics indicating poorer prognosis are 
associated with signiﬁ cantly higher breast cancer costs. Patients with metastatic disease 
carry the highest cost of care despite having shorter follow-up and poorer survival.
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OBJECTIVES: Hepatocellular carcinoma (HCC) is a rapidly progressing, fatal disease. 
However, little is known regarding the hospitalization burden for these patients. This 
study compares the burden of hospitalizations due to HCC and hepatobiliary condi-
tions relative to other nonhepatobiliary comorbid conditions. METHODS: Insurance 
claims (Janaury 1, 2000—December 31, 2008) from a geographically diverse, com-
mercially insured US population were used to identify a cohort of patients with > = 1 
HCC claim (index = 1st claim), age > = 18, and no other cancer diagnoses in the year 
prior to index. Hospitalizations were grouped by primary diagnosis (ICD-9) codes 
into the following categories: 1) HCC and hepatobiliary, and 2) nonhepatobiliary. 
Hospitalization burden was compared between these categories based on: number of 
hospitalizations, time to occurrence since HCC diagnosis, length of stay, and cost 
(2009 USD). The number of hospitalizations was compared using a sign test for 
patient-level differences. The remaining parameters were compared using general 
estimating equations to adjust for patients with multiple hospitalizations. RESULTS: 
This study identiﬁ ed 2927 HCC patients (mean age 50.4 years, 57% male) and 2192 
hospitalizations. The subset of patients with > = 1 hospitalization (n = 1083, 37%) 
had an average of 2.02 admissions per patient with a median of 11.8 follow-up 
months. Compared to the nonhepatobiliary hospitalizations, the HCC and hepatobili-
ary hospitalizations had: a higher number of admissions (0.40 vs. 0.35 per patient; P 
< 0.001), a shorter time to occurrence (112 vs. 330 days; P < 0.001), a longer length 
of stay (6.4 vs. 5.4 days; P < 0.007), and a higher average cost per admission ($48,539 
vs. 23,221; P < 0.001). The total cost of HCC and hepatobiliary hospitalizations was 
2.3 times higher than nonhepatobiliary hospitalizations ($56,451,173 vs. $23,894,444). 
CONCLUSIONS: HCC and hepatobiliary conditions accounted for the majority of 
the hospitalization burden in liver cancer patients. Future HCC therapies demonstrat-
ing reduced symptom progression may reduce the prevalence, duration, and cost of 
HCC and hepatobiliary-related hospitalizations.
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OBJECTIVES: Human papillomavirus (HPV) infection is a necessary cause of cervical 
cancer and is associated with a subset of other anogenital (anal, vulvar, vaginal, penile) 
and head/neck cancers (oral cavity, oropharynx/pharynx, larynx). The overall HPV-
related disease burden is considerable in Europe. This study aimed to assess the 
hospital costs of HPV-related cancers for both genders in France. METHODS: Hos-
pitalization costs were collected from a recent publication for cervical cancer and from 
the French national hospital database (PMSI) for other cancers. Costs included hos-
pital stays, radiotherapy, and chemotherapy sessions. Annual costs for each cancer 
were estimated from the health-care payers’ perspective. RESULTS: In 2006, the 
annual costs of cervical cancer were estimated at c43.9 million. In addition, vulvar 
and vaginal cancers were associated with c9.7 million annually. For anal cancer, the 
annual costs were c20.3 million (male: c6.3 million; female: c14 million). Penile cancer 
hospitalizations represented c2.6 million annually. The estimated annual costs for 
head/neck cancers in 2007 for males and females, respectively, were c54.4 and c17.1 
million for oral cavity, c128.2 and c21.7 million for oropharynx/pharynx, and c47.8 
and c5.5 million for larynx. Considering the assumed proportion of cancers attribut-
able to HPV (cervical: 100%; vulvar: 34.7%; vaginal 76.8%; anal: 84.2%; penile: 
46.7%; oral cavity: 16.0%; oropharynx: 28.2%; larynx: 21.3%, in Europe), the 
overall hospitalization costs due to HPV-related cancers were estimated at c61.6 
million in males and c70.8 million in females. CONCLUSIONS: The hospital burden 
of HPV-associated cancers in males is almost similar as in females, in France. This 
burden is probably underestimated since outpatient and indirect costs were not 
included.
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OBJECTIVES: In our study, we estimated social and economic burden of hepatocel-
lular carcinoma (HCC) in Russian Federation resulting from HCC from the position 
of public health-care system. METHODS: All types of costs were calculated—direct 
